Table 1.
Patient demographics and baseline characteristics
| Total number of patients | 341 |
| Age at CLL diagnosis, median (range) | 62 (28–86) |
| Age at COVID-19 diagnosis, median (range) | 69 (39–92) |
| Male, n (%) | 237 (69.5) |
| Median follow-up since COVID-19 diagnosis, weeks | 15.6 |
| Unmutated IGHV, n (%)* | 150 (56) |
| Mutated TP53 and/or deleted 17p† | 40 (13) |
| Obesity, n (%)‡ | 84 (25) |
| Hypogammaglobulinemia, n (%)§ | 97 (41) |
| Major comorbidities, n (%) | 238 (70) |
| CLL treatment history | |
| Never treated | 172 (37) |
| Previously treated | 214 (63) |
| Receiving treatment for CLL at COVID-19 diagnosis | 131 (38) |
| Chemoimmunotherapy, n (%) | 34 (26) |
| BCL-2 inhibitor, n (%) | 24 (18) |
| PI3K inhibitor, n (%) | 8 (6) |
| BTK inhibitor, n (%) | 63 (48) |
| Other treatment, n (%) | 3 (2) |
*IGHV available in 268 pts; †TP53 status available in 316 pts; ‡obesity defined as body mass index (BMI) ≥ 30; §data available in 235 pts; abbreviations: n, number of patients; CLL, chronic lymphocytic leukemia; IGHV immunoglobulin heavy chain variable region; TP53, tumour protein p53; BCL-2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; PI3K, phosphatidyl inositol 3-kinase